Table 1.
Latest Biologics and Oral Small Molecules for the Treatment of Chronic Plaque Psoriasis on Clinical Development
| Drug | Target | Type of Molecule | PASI75 (Drugs vs Placebo) | PASI90 (Drugs vs Placebo) | PASI 100 (Drugs vs Placebo) |
|---|---|---|---|---|---|
| Bimekizumab (UCB4940) | IL-17A and IL-17F | Humanized IgG1 monoclonal antibody | 95% vs 1% at week 16 | 85–91% vs 1% at week 16 | 59–68% vs 5% at week 16 |
| Mirikizumab (LY3074828) | p19 subunit of IL-23 | Humanized IgG4 monoclonal antibody | 90% vs 8% at week 16 | 74% vs 6% at week 16 | 32% vs 1% at week 16 |
| Netakimab (BCD085) | IL-17A | Humanized IgG1 monoclonal antibody | 83% vs 11% at week 24 | 68% vs 7% at week 24 | 49% vs 7% at week 24 |
| Deucravacitinib (BMS-986165) | TYK2 | Oral TYK2 selective inhibitor | 75% vs 7% at week 12 (phase II) | Not available | Not available |
| Piclidenoson (CF101) | A3AR | Oral agonist of the Gi protein associated A3AR | Not available | Not available | Not available |
Abbreviations: TYK2, tyrosine kinase 2 selective inhibitor; A3AR, A3 adenosine receptor (A3AR).